Coadministration of low-dose urokinase and abciximab in thrombolysis for lower limb ischemia. a safety study.
Haumer
M
M
Department of Angiology, General Hospital, Vienna, Austria.
Atteneder
M
M
Ahmadi
R
R
Schillinger
M
M
Minar
E
E
D000077284:Abciximab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000627:therapeutic use; D001157:Arterial Occlusive Diseases / Q000188:drug therapy; D002404:Catheterization; D004359:Drug Therapy, Combination; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000592:standards; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage* / Q000627:therapeutic use; D007511:Ischemia / Q000188:drug therapy*; D007866:Leg / Q000098:blood supply / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012008:Recurrence; D015912:Thrombolytic Therapy / Q000379:methods / Q000592:standards; D016896:Treatment Outcome; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage* / Q000592:standards; D014654:Vascular Patency / Q000187:drug effects
D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D014568:Urokinase-Type Plasminogen Activator; D000077284:Abciximab